Most Popular
-
1
Now is no time to add pressure on businesses: top executives
-
2
CJ CheilJedang to spur overseas growth with new Hungary, US plants
-
3
Blackpink's solo journeys: Complementary paths, not competition
-
4
Nationwide rail disruptions feared as union plans strike from Dec. 5
-
5
Seoul to host winter festival from Dec. 13
-
6
N. Korea, Russia court softer image: From animal diplomacy to tourism
-
7
Smugglers caught disguising 230 tons of Chinese black beans as diesel exhaust fluid
-
8
[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts
![[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/21/20241121050099_0.jpg&u=20241121172748)
-
9
Main opposition pushes to ease, not postpone, tax on crypto gains
-
10
Actor Song Joong-ki welcomes second child in Rome
![[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/21/20241121050099_0.jpg&u=20241121172748)
Around half of South Korean biotechnology or biopharmaceutical companies currently do not generate any sales, according to a recent report by the Korea Industrial Technology Association.
Of some 226 local bio companies surveyed by KOITA, 45.6 percent do not generate any sales today. Among those which do, 18.7 percent said that they began generating sales less than a year ago.
A majority of Korean bio firms surveyed were found to be small or midsized as well. Around 66.4 percent of the surveyed companies said they operate with less than 30 employees.
Of some 226 local bio companies surveyed by KOITA, 45.6 percent do not generate any sales today. Among those which do, 18.7 percent said that they began generating sales less than a year ago.
A majority of Korean bio firms surveyed were found to be small or midsized as well. Around 66.4 percent of the surveyed companies said they operate with less than 30 employees.
Some 65 percent of the firms responded that they lacked sufficient research and development professionals. Only 7.5 percent of the companies surveyed said they had a sufficient R&D workforce.
“Though considered a promising, high growth industry, Korea’s biopharma industry, aside from a few, consists mostly of companies which are unable to generate sales,” said KOITA director Kim Sung-woo, urging expanded government support for the industry.
By Sohn Ji-young (jys@heraldcorp.com)
![[Today’s K-pop] Babymonster logs 100m views with ‘Drip’ music video](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=642&simg=/content/image/2024/11/22/20241122050051_0.jpg&u=20241122172213)